Citations

Clear

75 citation(s) found for "Lee, Hong".

Abstract P157: Challenging Blood Pressure Control In Heart Failure Patients And Related Factors
Lee, Hong Seok c

Mayo Clinic

Hypertension | September 9, 2020 | Volume: 76 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.76.suppl_1.p157 Get It

Background: The 2017 ACC/AHA hypertension guidelines were released, and it specified blood pressure (BP) control goals in diverse situation. We will determine how the guideline can affect heart failure blood pressure control and risk factors for the control. There is not enough data how BP is controlled and what risk factors are related to controlled BP in heart failure patients according to the 2017 hypertension guideline. Method: 3276 heart failure patients who visited a community hospital for any medical reason were included and analyzed retrospectively from November 2017 to December 2018. Control of blood pressure will be defined based on the guidelines which show that heart failure patients’ blood pressure target is less than 130 /80 mmHg. ACE inhibitors/Aldosterone receptor blocker, diuretics(HCTZ, Furosemide, Butamex), Spironolactone, calcium channel blocker, and Angiotensin Receptor Neprilysin Inhibitor( Entresto), comorbidities(diabetes, chronic kidney disease, hyperlipidemia), age, gender, and ethnicities were collected and used for multi-variable adjusted logistic regression model. Results: 29.6% (555/1873) male patients were controlled based on the guidelines, on the contrary, 34.3%(482/1403) female patients revealed blood pressure control.The African american population’s BP was the most uncontrolled among all ethnicities. Multivariable logistic regression analysis was performed. Age of less than 65 years old [Odds ratio (OR): 2.81,95% Confidence Interval(CI): 2.41-3.26] was associated with controlled blood pressure. DM [OR: 0.71,95% CI: 0.61-0.82], beta-blocker [OR: 0.79,95% CI: 0.64-0.96] and LDL of more than 100mg/dl [OR: 0.57,95%, CI: 0.45-0.71] were noted to have significantly the uncontrolled BP. Conclusion: It appears about only one third of heart failure patients may be having their BP controlled based on 2017 ACC/AHA guideline. Beta-blocker were associated with uncontrolled blood pressure, which might suggest their dose of beta-blocker was not maximized for heart failure patients’ care. Clinicians may need to consider to try the higher dose if patients are tolerating. Elderly heart failure patients with DM or high LDL level (>100mg/dl)may need strict blood pressure control by better management of DM and LDL.
Reversible cardiac dysfunction in severe COVID‐19 infection, mechanisms and case report
Chao, Chieh‐Ju , DeValeria, Patrick A. , Sen, Ayan , Lee, Hong Seok , Pedrotty, Dawn , Patel, B. M. , Arsanjani, Reza , Naqvi, Tasneem Z. , Lee, Hong, Pedrotty, Dawn M, Arsanjani, Reza , Chao, Chieh-Ju

Mayo Clinic

Echocardiography | August 28, 2020 | Volume: 37 | Issue: 9 | Pages: 1465-1469

10.1111/echo.14807 | PMID 32856328 Get It

AbstractA previously healthy 49‐year‐old male patient presented with COVID‐19 infection and required mechanical ventilation and extracorporeal membrane oxygenation due to severe hypoxemia. Echocardiography showed cardiac dysfunction with an apical sparing strain pattern, which rapidly normalized within a week. Apical sparing myocardial strain in patients with COVID‐19 infection may suggest reverse‐type stress cardiomyopathy.
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Left-Sided Colonic Diverticulitis
Hall, Jason , Lee, Sang Hong , Stocchi, Luca , Paquette, Ian M., Hardiman, Karin M. , Lightner, Amy L. , Steele, Scott R. , Feingold, Daniel L.

Mayo Clinic

Diseases of the Colon & Rectum | May 8, 2020 | Volume: 63 | Issue: 6 | Pages: 728-747

10.1097/dcr.0000000000001679 | PMID 32384404 Get It

Essential Role of Patient Blood Management in a Pandemic: A Call for Action
Shander, Aryeh , Goobie, Susan M. , Aapro, Matti , Bisbe, Elvira , Callum, Jeannie , Erhard, J., Faraoni, David , Farmer, Shannon L. , Федорова, Т. А. , Gombotz, H., Gross, Irwin, Guinn, Nicole R. , Hamdorf, Jeffrey M. , Isbister, James P. , Ji, Hongwen , Kor, Daryl J. , Kurz, Johann, Lasocki, Sigismond , Leahy, Michael F. , Lee, Cheuk‐Kwong, Lee, Jeong Jae , Louw, Vernon , Meier, Jens , Mezzacasa, Anna, Múñoz, Manuel , Ozawa, Sherri , Pavesi, Marco , Shander, Nina, Spiess, Bruce D. , Thomson, Jackie, Trentino, Kevin M. , Zenger, Christoph, Hofmann, Axel , Warner, Matthew A. , Pérez-Calatayud, Ángel Augusto , Cushing, Melissa M. , Dyer, Wayne Bruce , Frank, Steven M. , Froessler, Bernd , Haas, Thorsten , Javidroozi, Mazyar , Kim, Young‐Woo , Lee, Cheuk Kwong , Spahn, Donat R. , Zenger, Christoph

Mayo Clinic

Anesthesia & Analgesia | April 2, 2020 | Volume: 131 | Issue: 1 | Pages: 74-85

10.1213/ane.0000000000004844 | PMID 32243296 Get It

The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic. Global health care now faces unprecedented challenges with widespread and rapid human-to-human transmission of SARS-CoV-2 and high morbidity and mortality with COVID-19 worldwide. Across the world, medical care is hampered by a critical shortage of not only hand sanitizers, personal protective equipment, ventilators, and hospital beds, but also impediments to the blood supply. Blood donation centers in many areas around the globe have mostly closed. Donors, practicing social distancing, some either with illness or undergoing self-quarantine, are quickly diminishing. Drastic public health initiatives have focused on containment and “flattening the curve” while invaluable resources are being depleted. In some countries, the point has been reached at which the demand for such resources, including donor blood, outstrips the supply. Questions as to the safety of blood persist. Although it does not appear very likely that the virus can be transmitted through allogeneic blood transfusion, this still remains to be fully determined. As options dwindle, we must enact regional and national shortage plans worldwide and more vitally disseminate the knowledge of and immediately implement patient blood management (PBM). PBM is an evidence-based bundle of care to optimize medical and surgical patient outcomes by clinically managing and preserving a patient’s own blood. This multinational and diverse group of authors issue this “Call to Action” underscoring “The Essential Role of Patient Blood Management in the Management of Pandemics” and urging all stakeholders and providers to implement the practical and commonsense principles of PBM and its multiprofessional and multimodality approaches.
Variations in hemoglobin measurement and eligibility criteria across blood donation services are associated with differing low‐hemoglobin deferral rates: a BEST Collaborative study
Zalpuri, Saurabh , Romeijn, Bas, Allara, Elias , Kamel, Hany , Gorlin, Jed B. , Vassallo, Ralph R. , Goto, Naoko, Flanagan, Peter , Speedy, Joanna, Castrén, Johanna, Culler, Liz, Sussmann, Harry, Prinsze, Femmeke J. , Belanger, Kevin, Tiberghien, Pierre , Cardenas, Jose M. , West, Kamille A. , Lee, Cheuk‐Kwong, James, Sian , Wells, Deanne, Sutor, Laurie J., Seltsam, Axel , Roden, Kimberly, Bohoněk, Miloš , Alcantara, Ramir , Angelantonio, Emanuele Di , Hurk, Katja van den , Group, BEST Collaborative Study, Vassallo, Ralph R , Gorlin, Jed , Di Angelantonio, Emanuele , Goldman, Mindy , Grégoire, Yves , Buser, Andreas , Kutner, José Mauro , Magnussen, Karin , Compernolle, Veerle , Cardenas, Jose Manuel, Gandhi, Manish J. , Lee, Cheuk Kwong , Wendel, Silvano , Coleman, Matthew , Steele, Whitney Randolph , Group, BEST Collaborative Study

Mayo Clinic

Transfusion | February 8, 2020 | Volume: 60 | Issue: 3 | Pages: 544-552

10.1111/trf.15676 | PMID 32034925 Get It

BACKGROUND Determination of blood donor hemoglobin (Hb) levels is a pre‐requisite to ensure donor safety and blood product quality. We aimed to identify Hb measurement practices across blood donation services and to what extent differences associate with low‐Hb deferral rates. METHODS An online survey was performed among Biomedical Excellence for Safer Transfusion (BEST) Collaborative members, extended with published data. Multivariable negative‐binomial regression models were built to estimate adjusted associations of minimum donation intervals, Hb cut‐offs (high, ≥13.5 g/dL in men or ≥ 12.5 g/dL in women, vs. lower values), iron monitoring (yes/no), providing or prescribing iron supplementation (yes/no), post‐versus pre‐donation Hb measurement and geographical location (Asian vs. rest), with low‐Hb deferral rates. RESULTS Data were included from 38 blood services. Low‐Hb deferral rates varied from 0.11% to 8.81% among men and 0.84% to 31.85% among women. Services with longer minimum donation intervals had significantly lower deferral rates among both women (rate ratio, RR 0.53, 95%CI 0.33‐0.84) and men (RR 0.53, 95%CI 0.31‐0.90). In women, iron supplementation was associated with lower Hb deferral rates (RR 0.47, 95%CI 0.23‐0.94). Finally, being located in Asia was associated with higher low‐Hb deferral rates; RR 9.10 (95%CI 3.89‐21.27) for women and 6.76 (95%CI 2.45‐18.68) for men. CONCLUSION Differences in Hb measurement and eligibility criteria, particularly longer donation intervals and iron supplementation in women, are associated with variations in low‐Hb deferral rates. These insights could help improve both blood donation service efficiency and donor care.
Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN)
Aschenbrenner, Andrew J. , James, Bryan D. , Wang, Guoqiao , Lim, Yen Ying , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Xiong, Chengjie , Perrin, Richard J. , Buckles, Virginia, Berman, Sarah , Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , O’Connor, Antoinette , Graff‐Radford, Neill R. , Gräber, Susanne, Martins, Ralph N. , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Morris, John C. , Bateman, Randall J. , Hassenstab, Jason , Network, Dominantly Inherited Alzheimer, Cruchaga, Carlos , O'Connor, Antoinette , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Benzinger, Tammie L S , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , McDade, Eric , Xiong, Chengjie , Allegri, Ricardo , Ghetti, Bernardino , Goldman, Jill , Karch, Celeste M. , Lee, Jae‐Hong , Schofield, Peter R. , Network, Dominantly Inherited Alzheimer, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 219-228

10.1002/alz.12010 | PMID 31914221 Get It

AbstractIntroductionAlthough some members of families with autosomal dominant Alzheimer's disease mutations learn their mutation status, most do not. How knowledge of mutation status affects clinical disease progression is unknown. This study quantifies the influence of mutation awareness on clinical symptoms, cognition, and biomarkers.MethodsMutation carriers and non‐carriers from the Dominantly Inherited Alzheimer Network (DIAN) were stratified based on knowledge of mutation status. Rates of change on standard clinical, cognitive, and neuroimaging outcomes were examined.ResultsMutation knowledge had no associations with cognitive decline, clinical progression, amyloid deposition, hippocampal volume, or depression in either carriers or non‐carriers. Carriers who learned their status mid‐study had slightly higher levels of depression and lower cognitive scores.DiscussionKnowledge of mutation status does not affect rates of change on any measured outcome. Learning of status mid‐study may confer short‐term changes in cognitive functioning, or changes in cognition may influence the determination of mutation status.
Tribute to Paul M. Vanhoutte, MD, PhD (1940–2019)
Baretella, Oliver , Blaise, Gilbert, Bond, Richard A. , Cai, Yin , Chan, C K, Chataigneau, Thierry, Chen, M., Chen, Hui , Cheng, Yanhua, Clément, Denis, Cohen, Richard A. , Collis, Michael J., Detremmerie, Charlotte Marie Simonne, Félétou, Michel, Flavahan, Nicolas, Gao, Yuansheng, Guo, Yumeng , Hoeffner, U., Houston, Donald S., Huang, Ianto Boscheng, Huang, Yü , Iliano, Stephane, Junquéro, Didier, Katušić, Zvonimir S. , Komori, Kimihiro , Lee, Mary Y. K. , Leung, Susan W.S. , Li, Zhuo-ming, Liang, Sophie Chaofan, Liu, J, Lüscher, Thomas F. , Michel, Frederic, Miller, Virginia M. , Mombouli, Jean-Vivien, Morrison, Keith , Muldoon, Sheila M., O’Rourke, Steve, Perrault, Louis P. , Quignard, Jean‐François , Rusch, Nancy J. , Sánchez‐Ferrer, Carlos F. , Shen, Kaikai , Shi, Yi , Song, Erfei , Sun, Kiwi W.Y., Tang, Eva Hoi Ching, Tuncer, Meral , Ende, Romana van den, Vedernikov, Yuri P., Verbeuren, Tony J., Webb, Clinton, Wong, Kenneth H.K., Xu, Cheng , Yang, Kangmin , Zellers, Thomas M. , Zhao, Yingzi , Zou, Qian , fellows, on behalf of Professor Paul M. Vanhoutte’s former, Boulanger, Chantal M. , Collis, Michael, Danser, A.H. Jan , Mey, Jo G. R. De , Duprez, Daniel , Huang, Ianto Bosheng , Michel, Frederic, Schini‐Kerth, Valérie B. , Shi, Yi, Taddei, Stefano , Tang, Eva H.C., Weigert, André Luiz Loureiro , Wong, Kenneth K. H., Ying, Fan, Shimokawa, Hiroaki , fellows, on behalf of Professor Paul M. Vanhoutte’s former

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | November 26, 2019 | Volume: 39 | Issue: 12 | Pages: 2445-2447

10.1161/atvbaha.119.313461 | PMID 31770032 Get It

Abstract LB-196: EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway
Gao, Xuyuan , Xu, Hang , Ho, Jcm , Chan, Oscar SH, Xu, Feng , Wang, Junwen , Lee, Victor , Tin, Vicky Pc, Xiao, Zhijie , Yam, Judy Wai Ping , Wong, Maria Pik , Wang, Junwen , Gao, Xuyuan, Wang, Siqi

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-196-LB-196

10.1158/1538-7445.am2018-lb-196 Get It

Abstract Lung cancer has the highest mortality across all cancers in the world. Epidermal growth factor receptor (EGFR) is commonly mutated in lung adenocarcinomas from Asian non-smoking females. These tumors usually respond to EGFR tyrosine kinase inhibitors (EGFR-TKI), but the outcomes vary in different patients. Though EGFR T790M, amplification of MET and other mechanisms have been shown to confer EGFR-TKI resistance, the molecular mechanisms in around 30% of patients are still unknown. To uncover novel candidate pathways of EGFR-TKI resistance, we analyzed the whole exome mutation profiles of pre-treatment, EGFR T790M-free lung adenocarcinomas with typical activating mutations (L858R, exon 19 deletions). Amongst 19 non-responding (NR) tumors without significant shrinkage after gefitinib or erlotinib treatment, 67 cancer-related genes showed coding region non-synonymous single nucleotide variations (SNV) or insertion-deletions (indels) but they were not detected in 22 responding tumors. Gene set enrichment analysis (GSEA) showed 14 of the 67 genes were involved in the EGFR and WNT signaling network (false discovery rate q=1.14 e-8 for EGFR and q=4.3 e-9 for WNT), including well-known TKI resistance-related genes PIK3CA, PTEN and NF1. Notably, ARID1A, which encodes a subunit of the chromatin remodeling complex, showed nonsense mutations in 2 NR but not responding tumors, which were validated by Sanger sequencing. More than 40% of ARID1A mutations in lung adenocarcinomas recorded in COSMIC were nonsense mutations or frameshift indels. Loss of function mutations of ARID1A have also been reported in various cancers, together suggesting ARID1A might be a tumor suppressor but its involvement in EGFR mutant lung cancers is unknown. To investigate the potential role of ARID1A, its expression was first studied using Kaplan-Meier plotter. Low expression of ARID1A is associated with significantly better overall survival than high expression level in lung adenocarcinoma patients (p=8.5 e-7). To test whether loss of ARID1A could cause TKI resistance, ARID1A was knocked down by shRNA in HCC827 lung cancer cell line harboring EGFR exon19 deletion. MTT cell viability assay using gefitinib showed increase of IC50. Western blot assay further showed ARID1A knockdown increased phosphorylation of AKT at Ser473. Together, the findings suggest loss of ARID1A could lead to EGFR bypass and promote activation of the downstream PI3K/AKT pathway, leading to EGFR TKI resistance. Overall, our findings suggest EGFR-TKI resistance mutations could be detected before TKI drug selection. Resistant gene mutations present in pre-treatment tumors could help to predict the treatment response. More specifically, our study identified a promising gene list involved in EGFR-TKI resistance, and suggested ARID1A loss could be a novel EGFR-TKI resistance mechanism. Citation Format: Xuyuan Gao, Hang Xu, James CM Ho, Oscar SH Chan, Feng Xu, Junwen Wang, Victor HF Lee, Vicky PC Tin, Zhijie Xiao, Siqi Wang, Judy WP Yam, Maria P Wong. EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-196.